# Bluespine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bluespine

- Industry: Healthcare IT
- Headquarters: New York, US
- Website: www.bluespine.io/
- Total disclosed funding: $7.2M
- Latest round: Seed (Nov 13, 2024)
- Investors on record: 1

## About

Based in New York, US, and founded in 2023 by co-founders David Talinovsky (CEO) and Gal Frishman (CTO), Bluespine, Inc. operates a provider of a claims review platform intended to prevent financial losses from healthcare overbilling. In November 2024, Bluespine, Inc. raised USD 7.2 million in seed funding led by Team8 Capital.

The company offers a claims review platform designed to prevent financial leakage due to medical overbilling. The core product leverages artificial intelligence (AI) to conduct detailed reviews of healthcare claims, ensuring that every potential savings opportunity is identified and recovered. Bluespine’s technology tailors its analysis based on the specific terms of individual plan contracts, allowing for customized rule sets that enhance accuracy in pinpointing errors. The platform serves a diverse client base, including employers, third-party administrators (TPAs), brokers, and auditors, who utilize Bluespine to optimize healthcare cost management and fulfill fiduciary obligations. The company's services are primarily aimed at the employer-sponsored health insurance market, with a focus on improving cost efficiency and compliance across various geographical markets, including the United States.

Bluespine's revenue model is structured around a performance-based pricing system, wherein the company charges fees only when it successfully saves clients money on their healthcare expenses. This aligns the company's financial interests with those of its clients, fostering a mutually beneficial relationship. Transactions typically occur through business-to-business (B2B) partnerships, where employers and other stakeholders engage Bluespine to leverage its AI-driven capabilities in claims analysis.

The company will use the funding to accelerate its adoption by US employers and brokers and support the creation of new roles in research and development. Future initiatives include the development of new features for their claims review platform aimed at enhancing user experience and increasing the efficiency of the claims analysis process. Bluespine plans to expand its operations into additional markets across the US by the end of 2025, targeting states with high healthcare spending.

## Funding rounds

- Seed, Nov 13, 2024, $7.2M — Team8 Capital

## Investors

- Team8 Capital (https://capitalatlas.ai/funds/team8-capital) — Seed